Reprocessing of Reusable Medical Devices, 45268-45269 [2011-19098]
Download as PDF
45268
Federal Register / Vol. 76, No. 145 / Thursday, July 28, 2011 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
Center for Drug Evaluation and
Research, Approach to Addressing
Drug Shortage; Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
rmajette on DSK89S0YB1PROD with NOTICES
VerDate Mar<15>2010
15:51 Jul 27, 2011
Jkt 223001
Dated: July 22, 2011.
David Dorsey,
Acting Deputy Commissioner for Policy,
Planning and Budget.
FDA is
announcing a public workshop
regarding CDER’s current approach to
addressing drug shortages. Given the
increasing number of drug shortages and
the attendant safety concerns for the
public’s health, it is important to
discuss the causes of these shortages, as
well as strategies to address them. This
public workshop will focus on
providing information and gaining
perspective from professional societies,
patient advocates, industry, consumer
groups, health care professionals,
researchers, and other interested
persons. The following topics will be
discussed:
• How CDER becomes aware of drug
shortages,
• Reasons behind drug shortages,
• Determination of medically
necessary products,
• CGMP (current good manufacturing
practice) and other compliance issues,
• Actions taken when a drug shortage
occurs, and
• Outcomes of mitigated drug
shortages.
Additional discussion will include
the public health impact of drug
shortages and what measures can be
taken to prevent the occurrence of a
drug shortage. The Agency encourages
professional societies, patient advocates,
industry, consumer groups, health care
professionals, researchers, and other
interested persons to attend this public
workshop.
Transcripts: Please be advised that as
soon as a transcript is available, it will
be accessible at https://
www.regulations.gov. It may be viewed
at the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD. A transcript will
also be available in either hardcopy or
on CD–ROM, after submission of a
Freedom of Information request. Written
requests are to be sent to the Division
of Freedom of Information (HFI–35),
Office of Management Programs, Food
and Drug Administration, 5600 Fishers
Lane, Rm. 6–30, Rockville, MD 20857.
[Docket No. FDA–2011–N–0294]
SUPPLEMENTARY INFORMATION:
The Food and Drug
Administration (FDA) is announcing a
public workshop regarding the approach
of the Center for Drug Evaluation and
Research (CDER) to addressing drug
shortages. This public workshop is
intended to provide information for, and
to gain additional insight from,
professional societies, patient advocates,
industry, consumer groups, health care
professionals, researchers, and other
interested persons about the causes and
impact of drug shortages, and possible
strategies for preventing or mitigating
drug shortages. The input from this
public workshop will help in
developing topics for further discussion
with industry and professional societies,
and other stakeholders and may help
the Agency to better address drug
shortage issues.
Date and Time: The public workshop
will be held on September 26, 2011,
from 8:30 a.m. to 4:30 p.m.
Location: The public workshop will
be held at 10903 New Hampshire Ave.,
Bldg. 31, rm. 1503 B and C (Great
Room), Silver Spring, MD 20993.
Information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘White Oak Conference Center
Parking and Transportation Information
for FDA Advisory Committee
Meetings.’’ Please note that visitors to
the White Oak Campus must enter
through Building 1. (https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm).
Contact Persons: Christine Moser or
Lori Benner, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 22, Rm. 6202, Silver Spring,
MD 20993–0002, 301–796–1300 or 301–
796–1600.
Registration: To register
electronically, e-mail registration
information (including name, title, firm
name, address, telephone, and fax
SUMMARY:
number) to dsworkshop@fda.hhs.gov by
September 19, 2011. Persons without
access to the Internet can call Christine
Moser at 301–796–1300 or Lori Benner
at 301–796–1300 to register. Registration
is free for the public workshop. Seating
will be available on a first-come, firstserved basis. Persons needing a sign
language interpreter or other special
accommodations should notify
Christine Moser or Lori Benner (see
Contact) at least 7 days in advance.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
[FR Doc. 2011–19031 Filed 7–27–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Reprocessing of Reusable Medical
Devices
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; request for comments.
The Food and Drug
Administration (FDA) is considering
factors affecting the reprocessing of
reusable medical devices, including
reprocessing quality, device design as it
relates to the reprocessing of reusable
medical devices, reprocessing
methodologies, validation
methodologies, and health care facility
best practices. This is part of an ongoing
effort to address patient exposure to
inadequately reprocessed reusable
medical devices. FDA would like to
provide another opportunity for public
comment by establishing a docket to
receive information and comments from
the public on factors affecting the
reprocessing of reusable medical
devices.
SUMMARY:
Submit either electronic or
written comments by September 26,
2011.
DATES:
You may submit comments,
identified with the FDA docket number
found in brackets in the heading of this
document, by any of the following
methods:
ADDRESSES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Written Submissions
Submit written submissions in the
following ways:
• FAX: 301–827–6870.
• Mail/Hand delivery/Courier (for
paper, disk, or CD–ROM submissions):
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852.
Instructions: All submissions received
must include the Agency name and
E:\FR\FM\28JYN1.SGM
28JYN1
Federal Register / Vol. 76, No. 145 / Thursday, July 28, 2011 / Notices
rmajette on DSK89S0YB1PROD with NOTICES
docket number for this notice. All
comments received may be posted
without change to https://
www.regulations.gov, including any
personal information provided. For
additional information on submitting
comments, see the ‘‘Comments’’ heading
of the SUPPLEMENTARY INFORMATION
section of this document.
Docket: For access to the docket to
read background documents or
comments received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Carol Krueger, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5437, Silver Spring,
MD 20993, 301–796–3241,
Carol.Krueger@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA has launched an effort focused
on the reprocessing of reusable medical
devices, including reprocessing quality,
device design as it relates to the
reprocessing of reusable medical
devices, reprocessing methodologies,
validation methodologies, and health
care facility best practices. As part of
this effort, FDA held a 2-day public
workshop on June 8 and 9, 2011, at
FDA’s White Oak Conference Center in
Silver Spring, MD. In the Federal
Register of May 2, 2011 (76 FR 24495),
FDA announced the workshop and
provided background information. The
workshop focused on medical devices
that are intended for reuse after
reprocessing, rather than third-party
reprocessing of single-use-only medical
devices. FDA has a Web cast of the
workshop available for viewing at
https://www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
ucm252205.htm. The workshop
included a public comment session.
On the workshop Web site (https://
www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
ucm252205.htm), FDA stated that
electronic comments regarding the
public workshop could be submitted to
https://www.regulations.gov until June
29, 2011. FDA inadvertently failed to
state this in the May 2, 2011, workshop
notice. Hence, https://
www.regulations.gov was not open for
submission of electronic comments.
FDA is publishing this notice to provide
another opportunity for public comment
VerDate Mar<15>2010
15:51 Jul 27, 2011
Jkt 223001
on reprocessing of reusable medical
devices issues.
Various types of medical devices used
in health care settings, from surgical
suction tips to complex endoscopes, are
designed and labeled for use on
multiple patients. Thousands of
reusable medical devices requiring
reprocessing are used every day in
diagnosing and treating patients. FDA
has received a number of reports of
patient exposure to inadequately
reprocessed medical devices and
subsequent health care-associated
infections (HAIs).
A definitive causal relationship
between reusable device reprocessing
and any patient infection is difficult to
establish because inadequate
reprocessing is not often investigated as
a cause when an HAI is diagnosed.
Several reports, however, contained
evidence suggesting that inadequate
reprocessing may have been a
contributing factor in microbial
transmission and subsequent infection.
Ensuring adequate reprocessing of
reusable medical devices could reduce
the incidence of HAIs associated with
the use of a reprocessed medical device.
This will decrease the public health
burden of HAIs in terms of morbidity,
mortality, and cost.
The adequate reprocessing of reusable
medical devices is a critically important
factor in protecting patient safety.
Inadequate reprocessing between
patients can result in the retention of
blood, tissue, and other biological debris
(soil) in reusable medical devices. This
soil can allow microbes to survive the
high level disinfection or sterilization
process, potentially resulting in HAIs or
other adverse patient outcomes. FDA
receives reports of problems in all steps
of medical device reprocessing,1
including cleaning, disinfecting, and
sterilizing. Manufacturers, health care
facilities, health care professionals, and
FDA all have a role in reducing the risk
of inadequately reprocessed medical
devices. To help address these issues,
FDA has engaged partners at the Centers
for Disease Control and Prevention, the
Centers for Medicaid and Medicare
Services, the Veterans Health
Administration, and The Joint
Commission, who bring valuable
expertise in disease control and health
care practices to this effort.
1 A more comprehensive description of
reprocessing steps is available in FDA’s draft
guidance ‘‘Processing/Reprocessing Medical
Devices in Health Care Settings: Validation
Methods and Labeling’’ at https://www.fda.gov/
MedicalDevices/DeviceRegulationandGuidance/
ReprocessingofReusableMedicalDevices/
default.htm.
PO 00000
Frm 00049
Fmt 4703
Sfmt 9990
45269
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
To assist interested parties, we are
asking for public comment on the
following issues:
1. What are the nature, scope, and
impact of reusable medical device
reprocessing problems that have been
observed? What are the causes of these
problems?
2. What factors or criteria to facilitate
reprocessing should be considered
when designing reusable medical
devices? How can the design process be
improved to better incorporate
cleanability as a design endpoint?
3. What factors or criteria should be
considered when developing
reprocessing instructions and validation
protocols for devices to be used in
various health care environments (e.g.,
hospital, ambulatory surgical center,
physician’s office), based on the draft
guidance document, ‘‘Processing/
Reprocessing Medical Devices in Health
Care Settings: Validation Methods and
Labeling,’’ available at https://
www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
ReprocessingofReusableMedicalDevices/
default.htm?
4. What factors or criteria should be
considered by a health care facility
when developing reusable device
reprocessing procedures and quality
assurance processes?
5. How should problems with
reusable medical device reprocessing be
identified, reported, and acted upon by
industry and users?
Dated: July 25, 2011.
Nancy K. Stade,
Deputy Director for Policy, Center for Devices
and Radiological Health.
[FR Doc. 2011–19098 Filed 7–27–11; 8:45 am]
BILLING CODE 4160–01–P
E:\FR\FM\28JYN1.SGM
28JYN1
Agencies
[Federal Register Volume 76, Number 145 (Thursday, July 28, 2011)]
[Notices]
[Pages 45268-45269]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-19098]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0294]
Reprocessing of Reusable Medical Devices
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is considering factors
affecting the reprocessing of reusable medical devices, including
reprocessing quality, device design as it relates to the reprocessing
of reusable medical devices, reprocessing methodologies, validation
methodologies, and health care facility best practices. This is part of
an ongoing effort to address patient exposure to inadequately
reprocessed reusable medical devices. FDA would like to provide another
opportunity for public comment by establishing a docket to receive
information and comments from the public on factors affecting the
reprocessing of reusable medical devices.
DATES: Submit either electronic or written comments by September 26,
2011.
ADDRESSES: You may submit comments, identified with the FDA docket
number found in brackets in the heading of this document, by any of the
following methods:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Written Submissions
Submit written submissions in the following ways:
FAX: 301-827-6870.
Mail/Hand delivery/Courier (for paper, disk, or CD-ROM
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Instructions: All submissions received must include the Agency name
and
[[Page 45269]]
docket number for this notice. All comments received may be posted
without change to https://www.regulations.gov, including any personal
information provided. For additional information on submitting
comments, see the ``Comments'' heading of the SUPPLEMENTARY INFORMATION
section of this document.
Docket: For access to the docket to read background documents or
comments received, go to https://www.regulations.gov and insert the
docket number, found in brackets in the heading of this document, into
the ``Search'' box and follow the prompts and/or go to the Division of
Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Carol Krueger, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5437, Silver Spring, MD 20993, 301-796-3241,
Carol.Krueger@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA has launched an effort focused on the reprocessing of reusable
medical devices, including reprocessing quality, device design as it
relates to the reprocessing of reusable medical devices, reprocessing
methodologies, validation methodologies, and health care facility best
practices. As part of this effort, FDA held a 2-day public workshop on
June 8 and 9, 2011, at FDA's White Oak Conference Center in Silver
Spring, MD. In the Federal Register of May 2, 2011 (76 FR 24495), FDA
announced the workshop and provided background information. The
workshop focused on medical devices that are intended for reuse after
reprocessing, rather than third-party reprocessing of single-use-only
medical devices. FDA has a Web cast of the workshop available for
viewing at https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm252205.htm. The workshop included a public
comment session.
On the workshop Web site (https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm252205.htm), FDA stated that
electronic comments regarding the public workshop could be submitted to
https://www.regulations.gov until June 29, 2011. FDA inadvertently
failed to state this in the May 2, 2011, workshop notice. Hence, https://www.regulations.gov was not open for submission of electronic
comments. FDA is publishing this notice to provide another opportunity
for public comment on reprocessing of reusable medical devices issues.
Various types of medical devices used in health care settings, from
surgical suction tips to complex endoscopes, are designed and labeled
for use on multiple patients. Thousands of reusable medical devices
requiring reprocessing are used every day in diagnosing and treating
patients. FDA has received a number of reports of patient exposure to
inadequately reprocessed medical devices and subsequent health care-
associated infections (HAIs).
A definitive causal relationship between reusable device
reprocessing and any patient infection is difficult to establish
because inadequate reprocessing is not often investigated as a cause
when an HAI is diagnosed. Several reports, however, contained evidence
suggesting that inadequate reprocessing may have been a contributing
factor in microbial transmission and subsequent infection. Ensuring
adequate reprocessing of reusable medical devices could reduce the
incidence of HAIs associated with the use of a reprocessed medical
device. This will decrease the public health burden of HAIs in terms of
morbidity, mortality, and cost.
The adequate reprocessing of reusable medical devices is a
critically important factor in protecting patient safety. Inadequate
reprocessing between patients can result in the retention of blood,
tissue, and other biological debris (soil) in reusable medical devices.
This soil can allow microbes to survive the high level disinfection or
sterilization process, potentially resulting in HAIs or other adverse
patient outcomes. FDA receives reports of problems in all steps of
medical device reprocessing,\1\ including cleaning, disinfecting, and
sterilizing. Manufacturers, health care facilities, health care
professionals, and FDA all have a role in reducing the risk of
inadequately reprocessed medical devices. To help address these issues,
FDA has engaged partners at the Centers for Disease Control and
Prevention, the Centers for Medicaid and Medicare Services, the
Veterans Health Administration, and The Joint Commission, who bring
valuable expertise in disease control and health care practices to this
effort.
---------------------------------------------------------------------------
\1\ A more comprehensive description of reprocessing steps is
available in FDA's draft guidance ``Processing/Reprocessing Medical
Devices in Health Care Settings: Validation Methods and Labeling''
at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/default.htm.
---------------------------------------------------------------------------
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. It is no
longer necessary to send two copies of mailed comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
To assist interested parties, we are asking for public comment on
the following issues:
1. What are the nature, scope, and impact of reusable medical
device reprocessing problems that have been observed? What are the
causes of these problems?
2. What factors or criteria to facilitate reprocessing should be
considered when designing reusable medical devices? How can the design
process be improved to better incorporate cleanability as a design
endpoint?
3. What factors or criteria should be considered when developing
reprocessing instructions and validation protocols for devices to be
used in various health care environments (e.g., hospital, ambulatory
surgical center, physician's office), based on the draft guidance
document, ``Processing/Reprocessing Medical Devices in Health Care
Settings: Validation Methods and Labeling,'' available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/default.htm?
4. What factors or criteria should be considered by a health care
facility when developing reusable device reprocessing procedures and
quality assurance processes?
5. How should problems with reusable medical device reprocessing be
identified, reported, and acted upon by industry and users?
Dated: July 25, 2011.
Nancy K. Stade,
Deputy Director for Policy, Center for Devices and Radiological Health.
[FR Doc. 2011-19098 Filed 7-27-11; 8:45 am]
BILLING CODE 4160-01-P